These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24650159)

  • 21. Prostate-specific antigen bounce in patients treated before 60 years old by iodine 125 brachytherapy for prostate cancer is frequent and not a prognostic factor.
    Charret J; Baumann AS; Eschwege P; Moreau JL; Bernier V; Falk AT; Salleron J; Peiffert D
    Brachytherapy; 2018; 17(6):888-894. PubMed ID: 30172752
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Kindts I; Stellamans K; Billiet I; Pottel H; Lambrecht A
    Strahlenther Onkol; 2017 Sep; 193(9):707-713. PubMed ID: 28488030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unusually high prostate-specific antigen bounce after prostate brachytherapy: Searching for etiologic factors.
    Chira C; Taussky D; Gruszczynski N; Meissner A; Larrivée S; Carrier JF; Donath D; Delouya G
    Brachytherapy; 2013; 12(6):603-7. PubMed ID: 23891340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen spikes after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.
    Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Hasegawa M; Fujii T; Konishi N; Fujimoto K
    BMC Urol; 2017 Aug; 17(1):62. PubMed ID: 28806948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup.
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Brachytherapy; 2006; 5(2):122-6. PubMed ID: 16644467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy.
    Tetreault-Laflamme A; Crook J; Hamm J; Pickles T; Keyes M; McKenzie M; Pai H; Bachand F; Morris J
    J Urol; 2018 Jan; 199(1):120-125. PubMed ID: 28827105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index lesion, the lower the PSA bounce.
    Quivrin M; Loffroy R; Cormier L; Mazoyer F; Bertaut A; Chambade D; Martin E; Maingon P; Walker P; Créhange G
    Radiother Oncol; 2015 Nov; 117(2):258-61. PubMed ID: 26324019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical outcomes and predictive factors by risk group after permanent iodine-125 seed implantation: Prospective cohort study in 2,316 patients.
    Katayama N; Nakamura K; Yorozu A; Kikuchi T; Fukushima M; Saito S; Dokiya T
    Brachytherapy; 2019; 18(5):574-582. PubMed ID: 31153759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
    Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between prostate-specific antigen bounce body fat distribution and body mass index in permanent seed brachytherapy for prostate cancer.
    Delouya G; Taussky D; Ji CR; Sylvestre MP; Donath D
    Brachytherapy; 2012; 11(3):214-8. PubMed ID: 21700507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term biochemical control and cause-specific survival in men with Gleason grade Group 4 and 5 prostate cancer treated with brachytherapy and external beam irradiation.
    Stone NN; Skouteris V; Stock RG
    Brachytherapy; 2020; 19(3):275-281. PubMed ID: 32217039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation.
    Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E
    Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer.
    Tanaka N; Asakawa I; Fujimoto K; Anai S; Hirayama A; Hasegawa M; Konishi N; Hirao Y
    BMC Urol; 2012 Sep; 12():28. PubMed ID: 22974428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Racial differences in the PSA bounce in predicting prostate cancer outcomes after brachytherapy: Evidence from the Department of Veterans Affairs.
    Slade AN; Dahman B; Chang MG
    Brachytherapy; 2020; 19(1):6-12. PubMed ID: 31611160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up.
    Caloglu M; Ciezki JP; Reddy CA; Angermeier K; Ulchaker J; Chehade N; Altman A; Magi-Galuzzi C; Klein EA
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):735-41. PubMed ID: 20646846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy--an Australian analysis.
    Zwahlen DR; Smith R; Andrianopoulos N; Matheson B; Royce P; Millar JL
    Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):179-87. PubMed ID: 20378267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.